In vitro and in vivo acute toxicity of an artificial butter flavoring.
Nárcia Mariana Fonseca NunesJurandy do Nascimento SilvaMicaely Lorrana Pereira ConceiçãoJoaquim Soares da Costa JúniorEdymilais da Silva SousaMaria das Dores Alves de OliveiraAntônia Maria das Graças Lopes CitóDalton DittzAna Paula PeronPaulo Michel Pinheiro FerreiraPublished in: Journal of toxicology and environmental health. Part A (2023)
Flavorings used in cookies, electronic cigarettes, popcorn, and breads contain approximately 30 chemical compounds, which makes it difficult to determine and correlate signs and symptoms of acute, subacute or chronic toxicity. The aim of this study was to characterize a butter flavoring chemically and subsequently examine the in vitro and in vivo toxicological profile using cellular techniques, invertebrates, and lab mammals. For the first time, the ethyl butanoate was found as the main compound of a butter flavoring (97.75%) and 24 h-toxicity assay employing Artemia salina larvae revealed a linear effect and LC 50 value of 14.7 (13.7-15.7) mg/ml (R 2 = 0.9448). Previous reports about higher oral doses of ethyl butanoate were not found. Observational screening with doses between 150-1000 mg/kg by gavage displayed increased amount of defecation, palpebral ptosis, and grip strength reduction, predominantly at higher doses. The flavoring also produced clinical signs of toxicity and diazepam-like behavioral changes in mice, including loss of motor coordination, muscle relaxation, increase of locomotor activity and intestinal motility, and induction of diarrhea, with deaths occurring after 48 h exposure. This substance fits into category 3 of the Globally Harmonized System. Data demonstrated that butter flavoring altered the emotional state in Swiss mice and disrupted intestinal motility, which may be a result of neurochemical changes or direct lesions in the central/peripheral nervous systems.
Keyphrases
- oxidative stress
- liver failure
- oxide nanoparticles
- respiratory failure
- drug induced
- spinal cord injury
- biofilm formation
- emergency department
- type diabetes
- skeletal muscle
- electronic health record
- depressive symptoms
- mass spectrometry
- staphylococcus aureus
- hepatitis b virus
- simultaneous determination
- resting state
- candida albicans
- cystic fibrosis
- irritable bowel syndrome
- chemotherapy induced
- gas chromatography